Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of recombinant human calcineurin subunit b

A technology of loading and drug administration, applied in the field of protein, can solve the problem of no killing or inhibition of gastric cancer cells MGC-803

Active Publication Date: 2016-12-28
HAIKOU QILI PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, there are no relevant reports on the killing or inhibiting effect of rhCNB on gastric cancer cell line MGC-803

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant human calcineurin subunit b
  • Application of recombinant human calcineurin subunit b
  • Application of recombinant human calcineurin subunit b

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Establishment of BALB / c Nude Mice Bearing Human Gastric Cancer Cell MGC-803 Subcutaneously Transplanted Tumor Model

[0036] Human gastric cancer cell MGC-803 was routinely cultured in vitro, digested and centrifuged to make a concentration of about 1×10 7 1 cell / mL cell suspension, 0.2 mL / only was inoculated subcutaneously in the right axilla of the mouse.

Embodiment 2

[0037] Example 2 Establishment of Orthotopic Transplantation Model of BALB / c Nude Mice Bearing Human Gastric Cancer Cell MGC-803

[0038] The well-grown subcutaneous xenografts were taken out and cut into tumor tissue pieces about 2×2×1 mm in size for later use. The animals to be inoculated were gas anesthetized with isoflurane and fed for 12 hours before the operation. After the animal is anesthetized, take the supine position, cut the skin horizontally layer by layer on the left side at 2-5 mm below the xiphoid process, and open about 1 cm, gently pull out the stomach with small forceps to expose it, and use 1# surgical thread to cut the tumor tissue "Purse-string suture" was performed on the side of the greater curvature of the stomach of nude mice near the door, and the tumor tissue was wrapped in it, and the skin was sutured layer by layer, and put back into the cage for normal feeding. Seven days after the operation, detection, grouping and drug administration were perf...

Embodiment 3

[0039] Embodiment 3 animal grouping

[0040] Take 90 inoculated nude mice and randomly divide them into rhCNB high-dose group for injection, rhCNB middle-dose group for injection, rhCNB low-dose group for injection, rhCNB dose-increasing group for injection and positive control rhCNB injection group according to bioluminescence detection data. Recombinant human interleukin-2 administration group, positive control cisplatin high-dose injection group, positive control cisplatin low-dose injection group, positive control hydroxycamptothecin injection group and vehicle control group Group, 10 in each group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the protein field, in particular to the application of recombinant human calmodulin phosphatase B subunit. The present invention mainly provides the application of rhCNB in ​​the preparation of drugs for killing and / or inhibiting gastric cancer cell MGC‑803. In the therapeutic effect of rhCNB for injection on BALB / c nude mice bearing human gastric cancer cell MGC-803 carcinoma in situ xenografts, the effective treatment of the tumor (compared with the vehicle control group, p<0.05) time was within 6 hours of continuous administration. After the second time, the tumor can be effectively controlled during the entire administration period. After 1 week of drug withdrawal, it still has a sustained and effective therapeutic effect on the tumor (compared with the vehicle control group, p<0.001), which is better than the positive control cisplatin for injection and hydroxycamptothecin for injection, and compared with recombinant human interleukin for injection. 2 quite.

Description

technical field [0001] The invention relates to the protein field, in particular to the application of recombinant human calmodulin phosphatase B subunit. Background technique [0002] Calcineurin (CN) is the only known Ca-dependent 2+ / CaM (calmodulin) protein phosphatase, composed of A, B subunits in a 1:1 ratio. The A subunit (CNA) is the catalytic subunit and the B subunit (CNB) is the regulatory subunit. CN plays an important role in the immune activation pathway and is a key enzyme for T cell activation. As a macromolecular enzyme protein, CN is easily inactivated and unstable, while CNB, as the regulatory subunit of the enzyme, can promote the activity of CNA, and has a small relative molecular mass and stable properties. Studies have shown that CNB can stimulate the proliferation of T cells and NK cells, enhance the killing activity of NK cells, enhance the phagocytosis of macrophages and other immune functions, and the recombinant human Calcineurin B subunit (rhC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/46A61P35/00
CPCA61K9/0019A61K38/465C12Y301/03016A61K9/08A61P35/04
Inventor 韩克胜符健黄宗文田树红韩丽芳
Owner HAIKOU QILI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com